S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
The Next Big Crisis Is Here (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
NASDAQ:PRVB

Provention Bio - PRVB Stock Forecast, Price & News

$8.77
+0.06 (+0.69%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.60
$8.89
50-Day Range
$7.77
$10.57
52-Week Range
$3.18
$10.88
Volume
629,975 shs
Average Volume
1.09 million shs
Market Capitalization
$764.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Provention Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
144.0% Upside
$21.40 Price Target
Short Interest
Bearish
8.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
-0.02mentions of Provention Bio in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$30.72 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.66) to ($1.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

546th out of 1,055 stocks

Pharmaceutical Preparations Industry

268th out of 519 stocks


PRVB stock logo

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

Should You Invest in Provention Bio (PRVB)?
PRVB.OQ - | Stock Price & Latest News | Reuters
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
12 Best Biotech Stocks to Buy Under $10
Why Shares of Provention Bio Went Up 30.3% in November
What 5 Analyst Ratings Have To Say About Provention Bio
Provention Bio (PRVB) Stock Falls Despite FDA Approval
Provention Bio diabetes drug to cost $13,850/vial
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
Provention Bio: Q3 Earnings Insights
These 2 Growth Stocks Have Potential Catalysts on the Way
See More Headlines
Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+144.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-114,430,000.00
Net Margins
-3,791.21%
Pretax Margin
-4,043.30%

Debt

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$1.75 per share

Miscellaneous

Free Float
75,769,000
Market Cap
$764.67 million
Optionable
Not Optionable
Beta
2.29

Key Executives

  • Ashleigh W. PalmerAshleigh W. Palmer
    Chief Executive Officer & Director
  • Christina Yi
    Chief Operating Officer
  • Thierry Chauche
    Chief Financial Officer
  • Francisco LeonFrancisco Leon
    Chief Scientific Officer
  • Eleanor Leni RamosEleanor Leni Ramos
    Chief Medical Officer













PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRVB shares.
View PRVB analyst ratings
or view top-rated stocks.

What is Provention Bio's stock price forecast for 2023?

6 Wall Street research analysts have issued 12 month price targets for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $30.00. On average, they expect the company's stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 144.0% from the stock's current price.
View analysts price targets for PRVB
or view top-rated stocks among Wall Street analysts.

How have PRVB shares performed in 2023?

Provention Bio's stock was trading at $10.57 at the start of the year. Since then, PRVB shares have decreased by 17.0% and is now trading at $8.77.
View the best growth stocks for 2023 here
.

When is Provention Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRVB earnings forecast
.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.12. The firm earned $0.76 million during the quarter, compared to analyst estimates of $0.88 million. Provention Bio had a negative net margin of 3,791.21% and a negative trailing twelve-month return on equity of 99.08%.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.21%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, Jason Hoitt and Sessa Capital (Master), LP.
View institutional ownership trends
.

How do I buy shares of Provention Bio?

Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $8.77.

How much money does Provention Bio make?

Provention Bio (NASDAQ:PRVB) has a market capitalization of $764.67 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 1/28/2023 by MarketBeat.com Staff